Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication

Por Quezada, Sergio A., Peggs, Karl S., Simpson, Tyler R., Allison, James P.
Publicado em 2011

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

Por Quezada, Sergio A., Peggs, Karl S., Simpson, Tyler R., Shen, Yuelei, Littman, Dan R., Allison, James P.
Publicado em 2008

Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics

Por Harvey, Christopher, Elpek, Kutlu, Duong, Ellen, Simpson, Tyler, Shu, ChengYi J, Shallberg, Lindsey, Wallace, Matthew, Sathyanarayanan, Sriram, Mabry, Robert, Briskin, Michael, Michaelson, Jennifer, Gajewski, Thomas F
Publicado no J Immunother Cancer (2015)

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

Por Quezada, Sergio A., Simpson, Tyler R., Peggs, Karl S., Merghoub, Taha, Vider, Jelena, Fan, Xiaozhou, Blasberg, Ronald, Yagita, Hideo, Muranski, Pawel, Antony, Paul A., Restifo, Nicholas P., Allison, James P.
Publicado em 2010

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

Por Simpson, Tyler R., Li, Fubin, Montalvo-Ortiz, Welby, Sepulveda, Manuel A., Bergerhoff, Katharina, Arce, Frederick, Roddie, Claire, Henry, Jake Y., Yagita, Hideo, Wolchok, Jedd D., Peggs, Karl S., Ravetch, Jeffrey V., Allison, James P., Quezada, Sergio A.
Publicado em 2013

An Acellular Biologic Scaffold Promotes Skeletal Muscle Formation in Mice and Humans with Volumetric Muscle Loss

Por Sicari, Brian M., Rubin, J. Peter, Dearth, Christopher L., Wolf, Matthew T., Ambrosio, Fabrisia, Boninger, Michael, Turner, Neill J., Weber, Douglas J., Simpson, Tyler W., Wyse, Aaron, Brown, Elke H. P., Dziki, Jenna L., Fisher, Lee E., Brown, Spencer, Badylak, Stephen F.
Publicado no Sci Transl Med (2014)

ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models

Por Hanson, Amanda, Elpek, Kutlu, Duong, Ellen, Shallberg, Lindsey, Fan, Martin, Johnson, Calvin, Wallace, Matthew, Mabry, George R., Sazinsky, Stephen, Pepper, Lauren, Shu, Chengyi J., Sathyanarayanan, Sriram, Zuerndorfer, Sarah, Simpson, Tyler, Gostissa, Monica, Briskin, Michael, Law, Deborah, Michaelson, Jennifer, Harvey, Christopher J.
Publicado no PLoS One (2020)

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Diminished Survival

Por Özdemir, Berna C., Pentcheva-Hoang, Tsvetelina, Carstens, Julienne L., Zheng, Xiaofeng, Wu, Chin-Chia, Simpson, Tyler, Laklai, Hanane, Sugimoto, Hikaru, Kahlert, Christoph, Novitskiy, Sergey V., Acosta, Ana DeJesus, Sharma, Padmanee, Heidari, Pedram, Mahmood, Umar, Chin, Lynda, Moses, Harold, Weaver, Valerie, Maitra, Anirban, Allison, James P., LeBleu, Valerie S., Kalluri, Raghu
Publicado em 2014